Executive Summary / Key Takeaways

• Acrivon Therapeutics is a clinical-stage precision oncology company leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to identify patients most likely to respond to its drug candidates, aiming to overcome limitations of traditional genomics-based approaches.
• The lead candidate, ACR-368 (a CHK1/CHK2 inhibitor), is in a potentially registrational Phase 2 trial for endometrial cancer, an indication prioritized based on AP3 predictions. Recent interim data showed a confirmed ORR of 35% and DCR of 80% in heavily pre-treated OncoSignature-positive patients, including a 33% ORR in those refractory to prior therapy.
• Acrivon's second clinical asset, ACR-2316 (a dual WEE1/PKMYT1 inhibitor), designed using AP3, is rapidly advancing in a Phase 1 trial, showing encouraging early signs of dose proportionality, target engagement, and initial tumor shrinkage at low dose levels.
• The company's cash, cash equivalents, and investments totaled $164.8 million as of March 31, 2025, providing a projected cash runway into the second quarter of 2027, bolstered by a $123.8 million net proceeds PIPE financing in April 2024.
• Key factors for investors to monitor include the continued progress and data from the ACR-368 registrational trial, the advancement and data readouts from the ACR-2316 Phase 1 study (with an update expected in H2 2025), and the company's ability to secure additional funding beyond its current runway to support its expanding pipeline and potential commercialization efforts.

Unlocking the Tumor's Code: Acrivon's Precision Proteomics Approach

Acrivon Therapeutics is carving out a distinct niche in the competitive oncology landscape by focusing on precision medicine powered by its unique Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3). Founded in 2018, the company has rapidly evolved from its inception, securing foundational intellectual property, including the in-licensing of its lead asset, ACR-368, from Eli Lilly (LLY) in 2021, and transitioning to a public entity via an IPO in late 2022. Acrivon's core strategy is built on the premise that understanding the dynamic protein signaling networks within tumor cells, rather than relying solely on static genetic mutations, can more accurately predict patient response to targeted therapies. This approach is designed to address the significant unmet need in oncology where many targeted treatments benefit only a small subset of patients identified by simple genetic biomarkers.

The AP3 platform represents Acrivon's key technological differentiator. It is engineered to provide an unbiased, comprehensive view of compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms. Unlike genomics-based methods that look for specific mutations, AP3 measures the functional state of cellular pathways by analyzing protein phosphorylation. This yields vast amounts of high-resolution quantitative data, which the platform's integrated computational tools – including the AP3 Interactome, Kinase Substrate Relationship Predictor, Data Portal, and Chatbot – are designed to convert into structured data amenable to generative AI analyses.

The tangible benefits of this technology, as articulated by the company, are multifaceted. AP3 is intended to enable streamlined, rational drug discovery through pathway-based drug design and optimization in intact cells. It facilitates the identification of rational drug combinations and, critically, allows for the creation of drug-specific proprietary OncoSignature companion diagnostics. These diagnostics are central to Acrivon's precision medicine model, aiming to identify the patients most likely to benefit from a specific drug. While precise, directly comparable quantitative performance metrics like percentage points of improved accuracy over all competitor methods are challenging to ascertain across the board, the company's focus on unbiased, proteome-wide analysis suggests a potential for superior prediction of drug sensitivity and resistance mechanisms compared to simpler biomarker approaches. This technological edge is intended to translate into a competitive moat, potentially leading to higher response rates in targeted patient populations, more efficient clinical trials, and ultimately, improved commercial potential for approved therapies.

Pipeline Momentum: ACR-368 and ACR-2316 Drive Clinical Progress

Acrivon's strategic focus is currently centered on advancing its two clinical-stage assets, ACR-368 and ACR-2316, both underpinned by the AP3 platform.

ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is the company's lead candidate. Following its in-licensing, Acrivon utilized AP3 for indication screening, which predicted sensitivity in endometrial cancer, a tumor type not previously studied in depth with this agent. This led to the initiation of a potentially registrational Phase 2 trial in patients with locally advanced or metastatic, recurrent endometrial cancer who had progressed after prior platinum-based chemotherapy and anti-PD-1 therapy. The potential of ACR-368 in this setting has been recognized by regulatory authorities, with the FDA granting Fast Track designation for ACR-368 monotherapy in OncoSignature-positive endometrial or platinum-resistant ovarian cancer, and Breakthrough Device designation for the ACR-368 OncoSignature assay for identifying patients who may benefit from treatment in both indications.

In March 2025, Acrivon reported positive interim clinical data from the ongoing endometrial cancer trial (based on a February 25, 2025 data snapshot). In 20 OncoSignature-positive (BM+) patients, who were generally heavily pre-treated (median 2 prior lines) and a majority of whom were refractory to their last prior therapy, ACR-368 monotherapy demonstrated a confirmed overall response rate (ORR) of 35% and a disease control rate (DCR) of 80%, with a median duration of response (mDOR) exceeding 5.6 months (not yet reached). Notably, in the 12 BM+ patients whose tumors were refractory to their last prior line of therapy (where the ORR was 0%), ACR-368 monotherapy achieved a confirmed ORR of 33% and DCR of 75%. For the 6 BM+ patients who had relapsed (but were not refractory) after their last prior therapy, the confirmed ORR was 50% and DCR was 100%, with mDOR exceeding 10 months (not yet reached). The company highlighted that 80% of BM+ patients showed tumor shrinkage and that the 35% confirmed ORR in all BM+ patients was more than double the best ORR observed in their last prior line of therapy (15%). These results provide initial clinical validation for the ACR-368 OncoSignature test's ability to prospectively identify responders and support endometrial cancer as a prioritized indication. Acrivon is also exploring the combination of ACR-368 with ultra low-dose gemcitabine (LDG) in OncoSignature-negative (BM-) patients, based on preclinical data and early clinical evidence suggesting LDG can sensitize tumors by upregulating OncoSignature biomarkers. Preliminary analysis in 38 BM- patients treated with the combination showed a confirmed ORR of 13%, comparable to their best ORR in the last prior line (17%).

Beyond ACR-368, Acrivon is leveraging its AP3 platform for internally discovered programs, including its second clinical asset, ACR-2316. This novel, selective WEE1/PKMYT1 inhibitor was designed using AP3 to achieve superior single-agent activity by activating not only CDK1 and CDK2 but also PLK1, aiming to drive pro-apoptotic cell death. ACR-2316 received IND clearance in September 2024, and the first patient was dosed in a Phase 1 trial in October 2024, reaching the clinic ahead of schedule. The Phase 1 study is evaluating safety, tolerability, PK profile, preliminary anti-tumor activity, and determining the recommended Phase 2 dose, with dose optimization guided by AP3-based drug target engagement. Early clinical observations reported in March 2025 are encouraging, with dose levels 1 and 2 cleared without safety concerns and dose level 3 fully enrolled. PK analysis showed approximate dose proportionality, and clinical MS-based AP3 profiling demonstrated significant drug target engagement at dose level 1. Initial clinical activity, including significant decrease in metastatic lesion size, was observed in a patient at dose level 3. An update on the ACR-2316 clinical data is anticipated in the second half of 2025. The company also has a preclinical cell cycle program with an undisclosed target, further utilizing the AP3 platform.

Competitive Positioning and Financial Realities

Acrivon operates within the highly competitive oncology market, facing established pharmaceutical giants like AstraZeneca (AZN), Merck (MRK), Bristol-Myers Squibb (BMY), and Pfizer (PFE), who have significant resources, broad pipelines, and established market presence, particularly in areas like DDR inhibition and solid tumors. While these large players often rely on genomics-based patient selection or broader biomarker approaches, Acrivon's competitive advantage lies in its unique AP3 Generative Phosphoproteomics platform. This technology's ability to analyze dynamic protein signaling offers a differentiated approach to patient selection, potentially leading to higher response rates in targeted populations compared to the broader application of competitor drugs. The company's focus on developing proprietary companion diagnostics, like the ACR-368 OncoSignature test, is a strategic move to capture value by linking drug efficacy directly to its predictive technology.

However, as a clinical-stage company, Acrivon faces significant competitive disadvantages compared to its large-cap peers. These include limited financial resources, lack of approved products and revenue, and the inherent risks associated with clinical development and regulatory approval. While Acrivon's technology may offer an edge in identifying responders, the large pharmaceutical companies benefit from economies of scale in R&D, manufacturing, and commercialization, often resulting in lower per-unit costs and greater efficiency in bringing products to market. Acrivon's current financial performance reflects its stage of development. For the three months ended March 31, 2025, the company reported a net loss of $19.70 million, an increase from the $16.50 million net loss for the same period in 2024. This widening loss is primarily driven by increased research and development expenses, which rose from $11.50 million in Q1 2024 to $15.40 million in Q1 2025. This increase reflects the costs associated with advancing the ACR-368 registrational trial and initiating the Phase 1 trial for ACR-2316, as well as growth in personnel-related costs due to increased headcount. General and administrative expenses remained relatively stable. The company did see an increase in total other income, net, primarily due to higher interest earned on its investments.

As of March 31, 2025, Acrivon held $164.8 million in cash, cash equivalents, and investments. This liquidity position was significantly bolstered by a private placement in April 2024, which generated aggregate net proceeds of $123.8 million. Based on its current operating plan, the company believes its existing capital resources are sufficient to fund operations into the second quarter of 2027. However, the company explicitly states that it will require additional funding to support its planned operating activities beyond this period. The ability to raise this additional capital is subject to market conditions and the availability of funding on acceptable terms, posing a significant risk. Failure to secure future funding could necessitate delays, reductions, or termination of development programs. The Zacks Consensus Estimate projects an earnings per share of -$2.70 for the fiscal year ending December 2025, reflecting the expected continued operating losses as the company invests heavily in R&D. The recent Zacks Rank upgrade to Buy, however, suggests a positive outlook on the company's earnings trajectory based on upward revisions in estimates, implying perceived improvement in the underlying business prospects.

Conclusion

Acrivon Therapeutics presents a compelling investment narrative centered on its differentiated AP3 Generative Phosphoproteomics platform and its potential to unlock precision oncology by accurately identifying patient responders. The positive interim data from the ACR-368 registrational trial in endometrial cancer provides initial validation for this approach and positions the asset for potential regulatory submission. The rapid progress and encouraging early observations from the ACR-2316 Phase 1 trial further demonstrate the platform's ability to generate promising internal pipeline candidates. While the company faces the inherent challenges of clinical development and intense competition from well-capitalized pharmaceutical companies, its unique technological foundation offers a potential competitive edge in developing targeted therapies with higher response rates in defined patient populations. Investors should closely monitor the continued clinical progress of both ACR-368 and ACR-2316, particularly upcoming data readouts, as well as the company's strategy for securing the necessary funding to advance its pipeline and navigate the path towards potential commercialization. The success of the AP3 platform in consistently identifying sensitive patients and translating preclinical promise into clinical efficacy remains the critical determinant of Acrivon's long-term value proposition.